Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

BACKGROUND: The trastuzumab, pertuzumab, and docetaxel (TPD) regimen is strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER) 2-positive breast cancer. Monitoring the host microenvironments in cancer plays a significant role in pr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Transl Med
Autors principals: Takada, Koji, Kashiwagi, Shinichiro, Goto, Wataru, Asano, Yuka, Takahashi, Katsuyuki, Takashima, Tsutomu, Tomita, Shuhei, Ohsawa, Masahiko, Hirakawa, Kosei, Ohira, Masaichi
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5883877/
https://ncbi.nlm.nih.gov/pubmed/29615076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-018-1460-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars